Lyfstone offers a convenient solution for conduction of rapid tests in near patient settings. Currently, the system is for research use only, although Lyfstone is working on obtaining the necessary documentation for CE-labelling and In-vitro diagnostic (IVD) usage in Europe and the US- market.
Lyfstone strive to deliver products and services at high standards to the orthopaedic community. Our lateral flow product portfolio comprise well-established biomarkers, and we can offer a wide selection of ELISA kits through our network of suppliers. For more information, please visit our product information site.
At present, there are several barriers for adapting state-of-the-art biomarker research into the clinic and, in the long run, Lyfstone offers an opportunity for a more rapid adaptation of such biomarkers into clinical usage. The Lyfstone concept offers a solution to low availability of biomarkers, complex sample-handling procedures, and lack of possibilities for conduction prospective observational studies.